SCHEDULE: Vanguard Discloses 5.17% Stake in Celldex Therapeutics

Vanguard Capital Management has reported beneficial ownership of 5.17% of Celldex Therapeutics' common stock as of March 31, 2026.

Summary

• Vanguard Capital Management, along with its affiliates, now beneficially owns 3,446,795 shares of Celldex Therapeutics' common stock.
• This holding represents 5.17% of the total class of securities.
• The filing indicates sole dispositive power over these shares.
• The reporting date for this ownership stake is March 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It represents a standard disclosure of institutional ownership and does not inherently signal positive or negative performance for Celldex Therapeutics, but rather Vanguard's investment strategy.

Positives

• Vanguard's significant stake suggests confidence in Celldex Therapeutics' long-term prospects.
• The reporting of sole dispositive power indicates clear control over the investment decisions for these shares.

Risks

• The filing does not contain specific risk factors related to this ownership change, but general market risks for biotechnology companies apply.
• Potential for future changes in Vanguard's stake could impact share price volatility.

Future Outlook

The filing itself is a disclosure of current ownership and does not contain forward-looking statements or guidance from Celldex Therapeutics. Vanguard's future actions regarding this stake are not specified.

Industry Context

StockSavvy.ai notes that significant institutional ownership, such as that reported by Vanguard, is common in the biotechnology sector, often indicating a belief in the company's research and development pipeline. However, this filing solely reflects Vanguard's investment position and not necessarily a strategic endorsement of Celldex's specific operations.

Stakeholder Impact

• Shareholders: The increased visibility of a major institutional investor like Vanguard may attract further investor interest, potentially influencing share price.
• Management: The presence of a significant institutional holder can sometimes lead to increased scrutiny and engagement on corporate strategy and governance.

Next Steps

• Monitor future filings for any changes in Vanguard's beneficial ownership.
• Observe Celldex Therapeutics' operational and clinical development updates for company-specific performance indicators.

Key Dates

Keywords

Celldex Therapeutics, Vanguard Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Biotechnology, Investment Management